Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT) [0.03%]
用拉什测量理论增强多发性硬化症影响量表的测量性能
Sophie Cleanthous,Stefan Cano,Elizabeth Kinter et al.
Sophie Cleanthous et al.
Background: Study objectives were to evaluate the Multiple Sclerosis Impact Scale (MSIS-29) and explore an optimized scoring structure based on empirical post-hoc analyses of data from the Phase III ADVANCE clinical trial...
Randomized controlled trial of an e-learning designed behavioral intervention for increasing physical activity behavior in multiple sclerosis [0.03%]
多发性硬化症患者增加体力活动行为的基于网络的行为干预的随机对照试验
Robert W Motl,Elizabeth A Hubbard,Rachel E Bollaert et al.
Robert W Motl et al.
Background: Internet-delivered, behavioral interventions represent a cost-effective, broadly disseminable approach for teaching persons with multiple sclerosis (MS) the theory-based skills, techniques, and strategies for ...
Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis [0.03%]
中国复发性多发性硬化症患者干扰素β中和抗体的流行率及其临床反应
Alexander Y Lau,W K Ip,Cheryl Au et al.
Alexander Y Lau et al.
Background: There are no data on neutralising antibodies to interferon-beta and its clinical implications in Chinese patients with multiple sclerosis (MS). ...
The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study [0.03%]
克拉屈滨片对后来根据现代标准确诊为多发性硬化症的单时相临床孤立综合征患者的有效性：ORACLE-MS研究结果
Mark S Freedman,Thomas P Leist,Giancarlo Comi et al.
Mark S Freedman et al.
Background: Multiple sclerosis (MS) diagnostic criteria have changed since the ORACLE-MS study was conducted; 223 of 616 patients (36.2%) would have met the diagnosis of MS vs clinically isolated syndrome (CIS) using the ...
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo [0.03%]
芬戈莫德与安慰剂中断治疗后多发性硬化疾病活动的比较研究
Patrick Vermersch,Ernst-Wilhelm Radue,Norman Putzki et al.
Patrick Vermersch et al.
Background: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. Objective: The obje...
M P Alvarenga,Sergio Schimidt,Rm Papais Alvarenga
M P Alvarenga
A major development over the past two decades was the recognition of recurrent neuromyelitis optica (NMO) as a particular central nervous system disorder different from multiple sclerosis (MS). Here we reviewed the epidemiology of NMO in La...
Verónica Rivas Alonso,José de Jesús Flores Rivera,Yamel Rito García et al.
Verónica Rivas Alonso et al.
Background: In today's globalised world, the heterogeneity of diseases such as multiple sclerosis has been studied since it has been suggested that ethnic differences, in conjunction with geographical and environmental fa...
Lilyana Amezcua,Jorge R Oksenberg,Jacob L McCauley
Lilyana Amezcua
Self-identified Hispanic/Latino individuals living with multiple sclerosis (MS) in the continental United States (US) are a diverse group that represents different cultural and ancestral backgrounds. A marked variability in the way MS affec...
Eli Skromne-Eisenberg,Laura Ordoñez-Boschetti,Irene Treviño-Frenk
Eli Skromne-Eisenberg
The treatment of multiple sclerosis (MS) has become increasingly complex during the last 10 years, mainly because of the advent of new and more potent disease-modifying therapies (DMTs). In Latin America, the therapeutic repertoire availabl...
Liliana Patrucco
Liliana Patrucco
The diagnosis of multiple sclerosis (MS) is based on neurological symptoms and signs, alongside evidence of dissemination of central nervous system (CNS) lesions in space and time. In the absence of a sensitive and specific diagnostic test,...